Ensign Peak Advisors
ATRA icon

Ensign Peak Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Ensign Peak Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,296
Closed -$217K – 1820
2022
Q3 		$217K Sell
2,296
-6,805
-75% -$764K ﹤0.01% 1849
2022
Q2 		$1.77M Buy
9,101
+2,558
+39% +$418K ﹤0.01% 850
2022
Q1 		$1.52M Buy
6,543
+5,826
+813% +$1.86M ﹤0.01% 995
2021
Q4 		$282K Sell
717
-2,032
-74% -$855K ﹤0.01% 1836
2021
Q3 		$1.23M Buy
+2,749
New +$985K ﹤0.01% 1346
2021
Q1 		– Sell
-1,996
Closed -$979K – 1830
2020
Q4 		$979K Hold
1,996
– – ﹤0.01% 1411
2020
Q3 		$647K Buy
+1,996
New +$680K ﹤0.01% 1456

Other funds holding ATRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return